## Laurence Katznelson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1492703/publications.pdf

Version: 2024-02-01

92 papers 8,183 citations

36 h-index 82 g-index

94 all docs 94 docs citations 94 times ranked 5163 citing authors

#	Article	IF	CITATIONS
1	Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. European Journal of Endocrinology, 2022, 186, P1-P33.	1.9	26
2	The role of growth hormone for fertility in women with hypopituitarism. Growth Hormone and IGF Research, 2022, 63, 101458.	0.5	O
3	Role of Radiation in the treatment of Cushing Disease. Pituitary, 2022, 25, 740-742.	1.6	4
4	A Pituitary Society update to acromegaly management guidelines. Pituitary, 2021, 24, 1-13.	1.6	158
5	Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement. Pituitary, 2021, 24, 143-145.	1.6	24
6	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, byaa205.	0.1	31
7	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
8	A pilot, randomized controlled trial of telementorship: A useful tool during social distancing. Journal of Clinical and Translational Research, 2021, 7, 66-71.	0.3	0
9	Performance Nutrition for Physician Trainees Working Overnight Shifts. Academic Medicine, 2021, Publish Ahead of Print, .	0.8	3
10	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	1.8	207
11	The New USMLE Step 1 Paradigm: An Opportunity to Cultivate Diversity of Excellence. Academic Medicine, 2020, 95, 1325-1328.	0.8	25
12	Managing complications of endoscopic transsphenoidal surgery in pituitary adenomas. Expert Review of Endocrinology and Metabolism, 2020, 15, 311-319.	1.2	10
13	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1133-1143.	0.6	4
14	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1144-1155.	0.6	4
15	Authors' response. Journal of the American Dental Association, 2019, 150, 568-569.	0.7	O
16	Beyond duty hours: leveraging large-scale paging data to monitor resident workload. Npj Digital Medicine, 2019, 2, 87.	5.7	5
17	A protected time policy to improve dental health among resident physicians. Journal of the American Dental Association, 2019, 150, 362-368.e6.	0.7	2
18	Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. European Journal of Endocrinology, 2019, 180, 31-40.	1.9	58

#	Article	IF	Citations
19	Prevention, diagnosis and treatment of Nelson's syndrome. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 63-66.	0.6	0
20	CyberKnife Radiosurgery in the Multimodal Management of Patients with Cushing Disease. World Neurosurgery, 2018, 112, e425-e430.	0.7	17
21	Adrenal Axis Insufficiency After Endoscopic Transsphenoidal Resection of Pituitary Adenomas. World Neurosurgery, 2018, 112, e869-e875.	0.7	11
22	CyberKnife robotic radiosurgery in the multimodal management of acromegaly patients with invasive macroadenoma: a single center's experience. Journal of Neuro-Oncology, 2018, 138, 291-298.	1.4	9
23	Nurse Telephonic Triage Service for After-hour Patient Calls in Neurosurgery. Annals of Surgery, 2018, 267, e67-e68.	2.1	1
24	Diabetes Insipidus following Endoscopic Transsphenoidal Surgery for Pituitary Adenoma. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 117-122.	0.4	41
25	Natural history of Rathke's cleft cysts: A retrospective analysis of a two centres experience. Clinical Endocrinology, 2018, 89, 178-186.	1.2	27
26	Practice transition in graduate medical education. Clinical Teacher, 2017, 14, 344-348.	0.4	13
27	Biochemical Control During Long-Term Follow-Up of 230 Adult Patients with Cushing Disease: A Multicenter Retrospective Study. Endocrine Practice, 2017, 23, 962-970.	1.1	23
28	Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians. Pituitary, 2017, 20, 422-429.	1.6	7
29	Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas. Endocrine Pathology, 2017, 28, 287-292.	<b>5.</b> 2	16
30	Encouraging Mindfulness in Medical House Staff via Smartphone App: A Pilot Study. Academic Psychiatry, 2017, 41, 646-650.	0.4	79
31	American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Update on Growth Hormone Stimulation Testing and Proposed Revised Cut-Point for the Glucagon Stimulation Test in the Diagnosis Of Adult Growth Hormone Deficiency. Endocrine Practice. 2016. 22, 1235-1244.	1.1	55
32	American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Diagnosis of Recurrence in Cushing Disease. Endocrine Practice, 2016, 22, 1436-1448.	1.1	50
33	Utility of a Glucocorticoid Sparing Strategy in the Management of Patients Following Transsphenoidal Surgery. Endocrine Practice, 2016, 22, 1033-1039.	1.1	8
34	Safety analysis of longâ€ŧerm budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery. International Forum of Allergy and Rhinology, 2016, 6, 568-572.	1.5	65
35	Giant Prolactinoma Presenting with Neck Pain and Structural Compromise of the Occipital Condyles. Journal of Neurological Surgery Reports, 2015, 76, e297-e301.	0.3	2
36	American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Management of Acromegaly Patients: What is the Role of Pre-Operative Medical Therapy?. Endocrine Practice, 2015, 21, 668-673.	1.1	44

#	Article	IF	CITATIONS
37	Aace/Ace Disease State Clinical Review: Diagnosis and Management of Midgut Carcinoids. Endocrine Practice, 2015, 21, 534-545.	1.1	22
38	American Association of Clinical Endocrinologists And American College of Endocrinology Disease State Clinical Review: Postoperative Management Following Pituitary Surgery. Endocrine Practice, 2015, 21, 832-838.	1.1	50
39	Long-Term Efficacy and Safety of Pegvisomant Therapy in Acromegaly. Endocrine Practice, 2015, 21, 296-298.	1.1	O
40	Bilateral adrenalectomy for Cushing's disease. Pituitary, 2015, 18, 269-273.	1.6	19
41	Radiotherapy vs. Radiosurgery in Treating Patients with Acromegaly: Systematic Review and Meta-Analysis. Endocrine Practice, 2015, , 1-33.	1.1	7
42	Nelson Syndrome: Update on Therapeutic Approaches. World Neurosurgery, 2015, 83, 1135-1140.	0.7	16
43	Cushing's disease: predicting long-term remission after surgical treatment. Neurosurgical Focus, 2015, 38, E13.	1.0	40
44	Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient. Pediatrics, 2015, 136, e1377-e1381.	1.0	8
45	Radiotherapy Versus Radiosurgery in Treating Patients with Acromegaly: A Systematic Review and Meta-Analysis. Endocrine Practice, 2015, 21, 943-956.	1.1	43
46	Utility of Adrenocorticotropic Hormone in Assessing the Response to Transsphenoidal Surgery for Cushing $\hat{a} \in \mathbb{T}^M$ s Disease. Endocrine Practice, 2014, 20, 1159-1164.	1.1	11
47	Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open″abel, phase I study. Journal of Clinical Pharmacology, 2014, 54, 1308-1317.	1.0	28
48	Global clinical response in C ushing's syndrome patients treated with mifepristone. Clinical Endocrinology, 2014, 80, 562-569.	1.2	37
49	Acromegaly: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3933-3951.	1.8	1,312
50	In Reply. Neurosurgery, 2014, 74, E143-E144.	0.6	0
51	Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults. Pituitary, 2013, 16, 220-230.	1.6	43
52	In Reply. Neurosurgery, 2013, 73, E557-E558.	0.6	0
53	Sustained Improvements in Plasma ACTH and Clinical Status in a Patient With Nelson's Syndrome Treated With Pasireotide LAR, a Multireceptor Somatostatin Analog. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1803-1807.	1.8	49
54	Clinical Characteristics and Pituitary Dysfunction in Patients with Metastatic Cancer to the sella. Endocrine Practice, 2013, 19, 914-919.	1.1	18

#	Article	IF	CITATIONS
55	Pituitary Centers of Excellence. Neurosurgery, 2012, 71, 916-926.	0.6	98
56	Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2039-2049.	1.8	409
57	Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 894-904.	1.8	452
58	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update. Endocrine Practice, 2011, 17, 1-44.	1.1	213
59	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly—2011 Update: Executive Summary. Endocrine Practice, 2011, 17, 636-646.	1.1	91
60	The dynamics of post-operative plasma ACTH values following transsphenoidal surgery for Cushing's disease. Pituitary, 2011, 14, 312-317.	1.6	24
61	Approach to the Patient with Persistent Acromegaly after Pituitary Surgery. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4114-4123.	1.8	30
62	Fatigue after traumatic brain injury: Association with neuroendocrine, sleep, depression and other factors. Brain Injury, 2010, 24, 1379-1388.	0.6	120
63	Pituitary Tumors. , 2010, , 477-486.		O
64	Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocrine-Related Cancer, 2009, 16, 1045-1055.	1.6	10
65	Acromegaly: where are we now?. Nature Reviews Endocrinology, 2009, 5, 420-422.	4.3	4
66	Alterations in body composition in acromegaly. Pituitary, 2009, 12, 136-142.	1.6	71
67	Prevalence and clinical demographics of cerebral salt wasting in patients with aneurysmal subarachnoid hemorrhage. Pituitary, 2009, 12, 347-351.	1.6	64
68	Non-surgical management of hormone-secreting pituitary tumors. Journal of Clinical Neuroscience, 2009, 16, 985-993.	0.8	18
69	The impact of hypopituitarism on function and performance in subjects with recent history of traumatic brain injury and aneurysmal subarachnoid haemorrhage. Brain Injury, 2009, 23, 639-648.	0.6	34
70	An update on treatment strategies for acromegaly. Expert Opinion on Pharmacotherapy, 2008, 9, 2273-2280.	0.9	8
71	Late Recurrences of Cushing's Disease after Initial Successful Transsphenoidal Surgery. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 358-362.	1.8	273
72	OUTCOMES AFTER REPEAT TRANSSPHENOIDAL SURGERY FOR RECURRENT CUSHING'S DISEASE. Neurosurgery, 2008, 63, 266-271.	0.6	146

#	Article	IF	CITATIONS
73	Pegvisomant for the treatment of acromegalyâ€"translation of clinical trials into clinical practice. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 514-515.	2.9	5
74	The role of inferior petrosal sinus sampling in the diagnostic localization of Cushing's disease. Neurosurgical Focus, 2007, 23, 1-6.	1.0	34
75	Current thinking on the management of the acromegalic patient. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 311-316.	1.2	4
76	Fatigue after TBI: Association with neuroendocrine abnormalities. Brain Injury, 2007, 21, 559-566.	0.6	86
77	Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary, 2007, 10, 19-25.	1.6	66
78	Approach to the evaluation of the GH/IGF-axis in patients with pituitary disease: which test to order. Pituitary, 2007, 10, 205-211.	1.6	4
79	Drug Insight: primary medical therapy of acromegaly. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 109-117.	2.9	12
80	Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men. European Journal of Endocrinology, 2006, 155, 867-875.	1.9	51
81	Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4465-4473.	1.8	319
82	Diagnosis and treatment of acromegaly. Growth Hormone and IGF Research, 2005, 15, 31-35.	0.5	28
83	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly. Endocrine Practice, 2004, 10, 213-225.	1.1	92
84	Diagnostic Errors after Inferior Petrosal Sinus Sampling. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3752-3763.	1.8	181
85	Effects of Growth Hormone Secretion on Body Composition in Patients with Crohn's Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5468-5472.	1.8	30
86	Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary, 2002, 5, 89-98.	1.6	24
87	Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, The, 2001, 358, 1754-1759.	6.3	585
88	Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose–effect relationship using dose–volume histogram analysis. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1079-1092.	0.4	182
89	Medical Therapy of Prolactinomas in Men. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1838-1846.	1.8	0
90	Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2976-2981.	1.8	73

#	Article	IF	CITATIONS
91	Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant. New England Journal of Medicine, 2000, 342, 1171-1177.	13.9	782
92	Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly 1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3419-3426.	1.8	512